In terms of overall case volume and prevalence, the Low Grade Glioma (LGG) segment holds a dominant position in the Glioma Diagnosis and Treatment Market. Classified as WHO Grade I and II tumors, LGGs are typically slower-growing than Glioblastoma, and their management strategy is significantly different. This segment’s dominance is attributed to the relatively higher frequency of these...